Reversing the negative effect of adenosine A1 receptor-targeted immunometabolism modulation on melanoma by a co-delivery nanomedicine for self-activation of anti-PD-L1 DNAzyme
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Adenosine and Purinergic Signaling · RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (64)
Show source-provided references
1. Hallmarks of cancer: after the next generation
2. Adenosine metabolism: emerging concepts for cancer therapy10.1016/j.ccell.2019.10.007 ↗
3. How the Warburg effect supports aggressiveness and drug resistance of cancer cells?10.1016/j.drup.2018.03.001 ↗
4. Cancer metabolism: looking forward10.1038/s41568-021-00378-6 ↗
5. Extracellular purines, purinergic receptors and tumor growth10.1038/onc.2016.206 ↗
6. ATP-driven temporal control over structure switching of polymeric micelles10.1021/acs.biomac.8b00769 ↗
7. Mechanisms of ATP release by inflammatory cells10.3390/ijms19041222 ↗
8. Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis10.1371/journal.pone.0009224 ↗
9. Beneficial and detrimental role of adenosine signaling in diseases and therapy10.1152/japplphysiol.00350.2015 ↗
10. Adenosine 5 '-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation10.1016/j.pharmthera.2005.04.013 ↗
11. Extracellular ATP and adenosine in cancer pathogenesis and treatment10.1016/j.trecan.2021.04.008 ↗
12. Targeting adenosine for cancer immunotherapy10.1186/s40425-018-0360-8 ↗
13. ATP and cancer immunosurveillance10.15252/embj.2021108130 ↗
14. High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors10.1155/2014/509027 ↗
15. Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival10.1007/s00262-020-02843-x ↗
16. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy10.1172/JCI89455 ↗
17. The adenosine pathway in immuno-oncology10.1038/s41571-020-0382-2 ↗
18. Immunity, inflammation and cancer: a leading role for adenosine10.1038/nrc3613 ↗
19. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment10.1038/s41568-018-0037-0 ↗
20. Differential expression of adenosine P1 receptor ADORA1 and ADORA2A associated with glioma development and tumor-associated epilepsy10.1007/s11064-016-1893-1 ↗
21. Adenosine A2b receptor promotes progression of human oral cancer
22. Targeting the negative feedback of adenosine-A2AR metabolic pathway by a tailored nanoinhibitor for photothermal immunotherapy10.1002/advs.202104182 ↗
23. Calcium phosphate-reinforced metal-organic frameworks regulate adenosine-mediated immunosuppression10.1002/adma.202102271 ↗
24. Synergistic effect of tumor chemo-immunotherapy induced by leukocyte-hitchhiking thermal-sensitive micelles10.1038/s41467-021-24902-2 ↗
25. Boosting cancer immunotherapy via the convenient A2AR inhibition using a tunable nanocatalyst with light-enhanced activity10.1002/adma.202106967 ↗
26. Omega-3 PUFAs induce apoptosis of gastric cancer cells via ADORA110.2741/4252 ↗
27. ADORA1 promotes nasopharyngeal carcinoma cell progression through regulation of PI3K/AKT/GSK-3 beta/beta-catenin signaling10.1016/j.lfs.2021.119581 ↗
28. ADORA1 promotes hepatocellular carcinoma progression via PI3K/AKT pathway10.2147/OTT.S272621 ↗
29. Adenosine A1 receptor, a target and regulator of estrogen receptor-alpha action, mediates the proliferative effects of estradiol in breast cancer10.1038/onc.2009.409 ↗
30. ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 axis10.1016/j.ccell.2020.02.006 ↗
31. Beneficial and detrimental role of adenosine signaling in diseases and therapy10.1152/japplphysiol.00350.2015 ↗
32. Plasma adenosine is linked to disease activity and response to treatment in patients with chronic spontaneous urticaria10.1111/all.14502 ↗
33. Elevated adenosine induces placental DNA hypomethylation independent of A2B receptor signaling in preeclampsia10.1161/HYPERTENSIONAHA.117.09536 ↗
34. Beneficial role of erythrocyte adenosine A2B receptor-mediated AMP-activated protein kinase activation in high-altitude hypoxia10.1161/CIRCULATIONAHA.116.021311 ↗
35. Acid-activatible micelleplex delivering siRNA-PD-L1 for improved cancer immunotherapy of CDK4/6 inhibition10.1016/j.cclet.2020.12.009 ↗
36. Programmed polymersomes with spatio-temporal delivery of antigen and dual-adjuvants for efficient dendritic cells-based cancer immunotherapy10.1016/j.cclet.2022.02.022 ↗
37. Immunogenic cell death-based cancer vaccines10.3389/fimmu.2021.697964 ↗
38. Applying nanotechnology to boost cancer immunotherapy by promoting immunogenic cell death10.1016/j.cclet.2021.10.074 ↗
39. Immunogenic cell stress and death10.1038/s41590-022-01132-2 ↗
40. In situ vaccination and gene-mediated PD-L1 blockade for enhanced tumor immunotherapy10.1016/j.cclet.2020.12.055 ↗
41. Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle10.1016/j.apsb.2021.05.031 ↗
42. Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy10.1016/j.biomaterials.2020.120604 ↗
43. Glutamine Antagonist Synergizes with Electrodynamic Therapy to Induce Tumor Regression and Systemic Antitumor Immunity10.1021/acsnano.1c08544 ↗
44. Dynamic adjust of non-radiative and radiative attenuation of AIE molecules reinforces NIR-II Imaging Mediated Photothermal Therapy and Immunotherapy10.1002/advs.202104793 ↗
45. Smart drug delivery systems for precise cancer therapy10.1016/j.apsb.2022.08.013 ↗
46. Oxygen-self-supplying and HIF-1α inhibiting core-shell nano-system for hypoxia-resistant photodynamic therapy10.1021/acsami.9b18112 ↗
47. Metal-phenolic networks for cancer theranostics10.1039/D0BM02064H ↗
48. A cyclic nano-reactor achieving enhanced photodynamic tumor therapy by reversing multiple resistances10.1186/s12951-021-00893-6 ↗
49. Metal-phenolic networks modified polyurethane as periosteum for bone regeneration10.1016/j.cclet.2021.09.105 ↗
50. Metal sensing by DNA10.1021/acs.chemrev.7b00063 ↗
51. Co-delivery of doxorubicin and DNAzyme using ZnO@polydopamine core-shell nanocomposites for chemo/gene/photothermal therapy10.1016/j.actbio.2020.04.041 ↗
52. Anti-PD-L1 DNAzyme loaded photothermal Mn2+/Fe3+ hybrid metal-phenolic networks for cyclically amplified tumor ferroptosis-immunotherapy
53. Core-shell nanosystems for self-activated drug-gene combinations against triple-negative breast cancer10.1021/acsami.0c15089 ↗
54. Theranostic DNAzymes10.7150/thno.17736 ↗
55. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers10.1038/bjc.2015.124 ↗
56. Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer immunotherapy10.1002/anie.201804882 ↗
57. Metal sensing by DNA10.1021/acs.chemrev.7b00063 ↗
58. ImmPort: disseminating data to the public for the future of immunology10.1007/s12026-014-8516-1 ↗
59. T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy10.1038/s41565-021-00972-7 ↗
60. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade10.1016/j.celrep.2016.12.019 ↗
61. The distribution and function of human memory T cell subsets in lung cancer10.1007/s12026-016-8882-y ↗
62. Thrombospondin-1, vascular endothelial growth factor expression and microvessel density in renal cell carcinoma and their relationship with multifocality10.1016/S0302-2838(03)00192-1 ↗
63. Expression of Bcl-X(L), an antiapoptotic member of the Bcl-2 family, in esophageal squamous cell carcinoma
64. A cyclic nano-reactor achieving enhanced photodynamic tumor therapy by reversing multiple resistances10.1186/s12951-021-00893-6 ↗